PE20160238A1 - Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion - Google Patents

Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion

Info

Publication number
PE20160238A1
PE20160238A1 PE2016000091A PE2016000091A PE20160238A1 PE 20160238 A1 PE20160238 A1 PE 20160238A1 PE 2016000091 A PE2016000091 A PE 2016000091A PE 2016000091 A PE2016000091 A PE 2016000091A PE 20160238 A1 PE20160238 A1 PE 20160238A1
Authority
PE
Peru
Prior art keywords
pyrazinamide
ethambutol
isoniazid
preparation process
antituberculosis
Prior art date
Application number
PE2016000091A
Other languages
English (en)
Inventor
Kumar Amith
Prasad Kum
Madavan Bindu
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51212860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160238(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20160238A1 publication Critical patent/PE20160238A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a un comprimido monocapa para uso en el tratamiento de la tuberculosis que comprenden una mezcla de: a) granulos que comprenden isoniazid, pirazinamida, etambutol o una sal farmaceuticamente aceptable de este y al menos un aglutinante de granulacion, rifampicina en forma de polvo, excipientes extragranulares, en el que todos los granulos tienen un tamano de particula que es menor de 0,599 mm, preferiblemente menor de 0,5 mm, mas preferiblemente menor de 0,422 mm. Tambien se refiere a su proceso de preparacion caracterizado porque comprende una etapa de granulacion humeda de isoniazid, pirazinamida y etambutol con una disolucion acuosa de un aglutinante de granulacion para obtener granulos
PE2016000091A 2013-07-26 2014-07-22 Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion PE20160238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3343CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
PE20160238A1 true PE20160238A1 (es) 2016-05-05

Family

ID=51212860

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000091A PE20160238A1 (es) 2013-07-26 2014-07-22 Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion

Country Status (18)

Country Link
US (1) US9814711B2 (es)
EP (1) EP3024445B1 (es)
JP (1) JP2017501117A (es)
CN (1) CN105407874A (es)
AU (1) AU2014295100B2 (es)
CA (1) CA2918828A1 (es)
CL (1) CL2016000180A1 (es)
HK (1) HK1218721A1 (es)
IL (1) IL243370A0 (es)
MX (1) MX2016001156A (es)
MY (1) MY174007A (es)
PE (1) PE20160238A1 (es)
PH (1) PH12016500118A1 (es)
RU (1) RU2672879C2 (es)
SG (1) SG11201510699WA (es)
TW (1) TW201601716A (es)
WO (1) WO2015011163A1 (es)
ZA (1) ZA201600108B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001155A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.
KR20180126511A (ko) * 2016-04-08 2018-11-27 큐어테크 바이오 에이비 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도
EP3691619A1 (en) * 2017-10-05 2020-08-12 Quretech Bio AB Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
CN108186638A (zh) * 2018-03-08 2018-06-22 重庆华邦制药有限公司 异烟肼的药物组合物
AU2022405079A1 (en) * 2021-12-07 2024-06-27 An2 Therapeutics, Inc. Combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
NZ518216A (en) * 2000-08-09 2004-11-26 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
WO2002087547A1 (en) 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
RU2195937C1 (ru) * 2002-02-06 2003-01-10 НИИ молекулярной медицины ММА им. И.М.Сеченова Комбинированный противотуберкулезный препарат (ризобутол)
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
EP1711182A1 (en) * 2004-02-04 2006-10-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of antituberculosis drugs
TWI368509B (en) 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
AP2012006119A0 (en) 2009-07-31 2012-02-29 Cadila Pharmaceuticals Ltd Pharmaceutical composition of isoniazid.
WO2012013756A2 (fr) * 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
MX2016001155A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.
RU2682178C2 (ru) 2013-07-26 2019-03-15 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления

Also Published As

Publication number Publication date
EP3024445B1 (en) 2019-01-09
MX2016001156A (es) 2016-04-29
CA2918828A1 (en) 2015-01-29
WO2015011163A1 (en) 2015-01-29
PH12016500118A1 (en) 2016-04-25
IL243370A0 (en) 2016-02-29
RU2672879C2 (ru) 2018-11-20
AU2014295100B2 (en) 2019-01-03
HK1218721A1 (zh) 2017-03-10
US9814711B2 (en) 2017-11-14
JP2017501117A (ja) 2017-01-12
CN105407874A (zh) 2016-03-16
MY174007A (en) 2020-03-03
AU2014295100A1 (en) 2016-02-11
RU2016106336A3 (es) 2018-05-17
EP3024445A1 (en) 2016-06-01
SG11201510699WA (en) 2016-01-28
RU2016106336A (ru) 2017-08-31
CL2016000180A1 (es) 2016-06-24
US20160158226A1 (en) 2016-06-09
ZA201600108B (en) 2017-04-26
TW201601716A (zh) 2016-01-16

Similar Documents

Publication Publication Date Title
PE20160238A1 (es) Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
SA515361055B1 (ar) نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
JP2015078230A5 (es)
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
MX2015013845A (es) Polvos secos de tiotropio.
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PH12016502272A1 (en) Ceritinib formulation
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
IN2014CH02034A (es)
AR109253A1 (es) Composición de teneligliptina y metformina y proceso para prepararla
MX2019001190A (es) Composicion de liberacion sostenida que comprende tolcapona micronizada.
CL2016000384A1 (es) Uso de una forma de dosificación de liberación extendida de arbaclofeno que comprende una primera dosis y una segunda dosis para administrar en un período de 24 horas, donde la primera dosis es administrada en estado alimentado y la segunda dosis en estado de ayuno; o la primera dosis en estado de ayuno y la segunda dosis en estado alimentado
AR106847A1 (es) Formulaciones farmacéuticas tópicas para tratar afecciones inflamatorias